Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice

Hannah M. Davis, Alyson L. Essex, Sinai Valdez, Padmini J. Deosthale, Mohammad W. Aref, Matthew Allen, Andrea Bonetto, Lilian Plotkin

Research output: Contribution to journalArticle

Abstract

Loss of bone and muscle mass are two major clinical complications among the growing list of chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. However, whether short-term pharmacologic RAGE inhibition can prevent early bone and muscle loss in aging is unknown. To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease. Azeliragon did not prevent the aging-induced alterations in bone geometry or mechanics, likely due to its differential effects [direct vs. indirect] on bone cell viability/function. On the other hand, Azeliragon attenuated the aging-related body composition changes [fat and lean mass] and reversed the skeletal muscle alterations induced with aging. Interestingly, while Azeliragon induced similar metabolic changes in bone and skeletal muscle, aging differentially altered the expression of genes associated with glucose uptake/metabolism in these two tissues, highlighting a potential explanation for the differential effects of Azeliragon on bone and skeletal muscle in middle-aged mice. Overall, our findings suggest that while short-term pharmacologic RAGE inhibition did not protect against early aging-induced bone alterations, it prevented against the early effects of aging in skeletal muscle.

Original languageEnglish (US)
Pages (from-to)89-102
Number of pages14
JournalBone
Volume124
DOIs
StatePublished - Jul 1 2019

Fingerprint

Skeletal Muscle
Bone and Bones
Muscles
Advanced Glycosylation End Product-Specific Receptor
Inhibition (Psychology)
S100 Proteins
Staphylococcal Protein A
Body Composition
Mechanics
Cell Survival
Alzheimer Disease
Chronic Disease
Fats
Pathology
Ligands
Inflammation
Gene Expression
Glucose

Keywords

  • Aging
  • Inflammation
  • Metabolism
  • Osteoporosis
  • RAGE
  • Skeletal muscle

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice. / Davis, Hannah M.; Essex, Alyson L.; Valdez, Sinai; Deosthale, Padmini J.; Aref, Mohammad W.; Allen, Matthew; Bonetto, Andrea; Plotkin, Lilian.

In: Bone, Vol. 124, 01.07.2019, p. 89-102.

Research output: Contribution to journalArticle

Davis, Hannah M. ; Essex, Alyson L. ; Valdez, Sinai ; Deosthale, Padmini J. ; Aref, Mohammad W. ; Allen, Matthew ; Bonetto, Andrea ; Plotkin, Lilian. / Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice. In: Bone. 2019 ; Vol. 124. pp. 89-102.
@article{0fb33763c50c4d51bcdc1e7a7618f73b,
title = "Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice",
abstract = "Loss of bone and muscle mass are two major clinical complications among the growing list of chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. However, whether short-term pharmacologic RAGE inhibition can prevent early bone and muscle loss in aging is unknown. To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease. Azeliragon did not prevent the aging-induced alterations in bone geometry or mechanics, likely due to its differential effects [direct vs. indirect] on bone cell viability/function. On the other hand, Azeliragon attenuated the aging-related body composition changes [fat and lean mass] and reversed the skeletal muscle alterations induced with aging. Interestingly, while Azeliragon induced similar metabolic changes in bone and skeletal muscle, aging differentially altered the expression of genes associated with glucose uptake/metabolism in these two tissues, highlighting a potential explanation for the differential effects of Azeliragon on bone and skeletal muscle in middle-aged mice. Overall, our findings suggest that while short-term pharmacologic RAGE inhibition did not protect against early aging-induced bone alterations, it prevented against the early effects of aging in skeletal muscle.",
keywords = "Aging, Inflammation, Metabolism, Osteoporosis, RAGE, Skeletal muscle",
author = "Davis, {Hannah M.} and Essex, {Alyson L.} and Sinai Valdez and Deosthale, {Padmini J.} and Aref, {Mohammad W.} and Matthew Allen and Andrea Bonetto and Lilian Plotkin",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.bone.2019.04.012",
language = "English (US)",
volume = "124",
pages = "89--102",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice

AU - Davis, Hannah M.

AU - Essex, Alyson L.

AU - Valdez, Sinai

AU - Deosthale, Padmini J.

AU - Aref, Mohammad W.

AU - Allen, Matthew

AU - Bonetto, Andrea

AU - Plotkin, Lilian

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Loss of bone and muscle mass are two major clinical complications among the growing list of chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. However, whether short-term pharmacologic RAGE inhibition can prevent early bone and muscle loss in aging is unknown. To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease. Azeliragon did not prevent the aging-induced alterations in bone geometry or mechanics, likely due to its differential effects [direct vs. indirect] on bone cell viability/function. On the other hand, Azeliragon attenuated the aging-related body composition changes [fat and lean mass] and reversed the skeletal muscle alterations induced with aging. Interestingly, while Azeliragon induced similar metabolic changes in bone and skeletal muscle, aging differentially altered the expression of genes associated with glucose uptake/metabolism in these two tissues, highlighting a potential explanation for the differential effects of Azeliragon on bone and skeletal muscle in middle-aged mice. Overall, our findings suggest that while short-term pharmacologic RAGE inhibition did not protect against early aging-induced bone alterations, it prevented against the early effects of aging in skeletal muscle.

AB - Loss of bone and muscle mass are two major clinical complications among the growing list of chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. However, whether short-term pharmacologic RAGE inhibition can prevent early bone and muscle loss in aging is unknown. To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease. Azeliragon did not prevent the aging-induced alterations in bone geometry or mechanics, likely due to its differential effects [direct vs. indirect] on bone cell viability/function. On the other hand, Azeliragon attenuated the aging-related body composition changes [fat and lean mass] and reversed the skeletal muscle alterations induced with aging. Interestingly, while Azeliragon induced similar metabolic changes in bone and skeletal muscle, aging differentially altered the expression of genes associated with glucose uptake/metabolism in these two tissues, highlighting a potential explanation for the differential effects of Azeliragon on bone and skeletal muscle in middle-aged mice. Overall, our findings suggest that while short-term pharmacologic RAGE inhibition did not protect against early aging-induced bone alterations, it prevented against the early effects of aging in skeletal muscle.

KW - Aging

KW - Inflammation

KW - Metabolism

KW - Osteoporosis

KW - RAGE

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=85064890472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064890472&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2019.04.012

DO - 10.1016/j.bone.2019.04.012

M3 - Article

VL - 124

SP - 89

EP - 102

JO - Bone

JF - Bone

SN - 8756-3282

ER -